India Pharma Outlook Team | Monday, 11 August 2025
Cosmo Pharmaceuticals N.V., a global leader in AI-powered healthcare and specialty pharmaceuticals, has renewed its multi-year manufacturing and supply agreement with Takeda for Mesalazine MMX 1200 mg - marketed as Lialda in the USA and Mezavant in Europe. The oral once-daily therapy is indicated for the management of ulcerative colitis and the agreement affirms Cosmo's position as a trusted global producer of medicines.
“This renewal is a testament to our long-standing relationship with Takeda and our best-in-class manufacturing capabilities,” said Giovanni Di Napoli, CEO of Cosmo. “This solidifies our commitment to innovation, sustainability, and excellence with Takeda; and it is aligned with our Vision 2030 - enhance trusted partnerships and expand our CDMO leadership globally."
Cosmo is continuing production at its advanced 18,000 m² facility at Lainate, Italy, one of seven sites certified by global regulatory authorities. The Lainate site has provided pharmaceutical manufacturing for over 30 years and represents the backbone of high-quality, efficient and environmentally friendly production. The quality management system is ISO 13485 certified and is committed to continuous improvement and creating customer value.
Also Read: Personalized Hygiene Care Tailoring Products to Individual Needs
Cosmo participates in MedTech AI, dermatology, gastrointestinal disease, and contract development and manufacturing (CDMO) business. The company conceptualizes, engineers, and produces advanced medical solutions on behalf of its global pharmaceutical and MedTech partners. Cosmo strives to deliver technologies that respond to urgent healthcare needs and improve patients' overall outcomes as they use these therapies.
The renewed agreement with Takeda demonstrates the strategic relevance of reliable, high-standard manufacturing to ensure patients have access to required therapies for chronic conditions, such as ulcerative colitis.
